Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W P Forbes

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
Arteriosclerosis, Thrombosis, and Vascular Biology|December 16, 1998
Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudicationM B Elam, J Heckman, J R Crouse, et al.
Alimentary Pharmacology & Therapeutics|October 29, 2014
A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activityR Khanna, G Zou, G D'Haens, et al.
Alimentary Pharmacology & Therapeutics|August 19, 2011
Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled studyA Sanyal, Z M Younossi, N M Bass, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
Arteriosclerosis, Thrombosis, and Vascular Biology|December 16, 1998
Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudicationM B Elam, J Heckman, J R Crouse, et al.
Alimentary Pharmacology & Therapeutics|October 29, 2014
A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activityR Khanna, G Zou, G D'Haens, et al.
Alimentary Pharmacology & Therapeutics|August 19, 2011
Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled studyA Sanyal, Z M Younossi, N M Bass, et al.
Pageof 3